AR-V7 expression in circulating prostate cancer cells is also correlated with resistance to enzalutamide and abiraterone, inhibitors of AR signaling [85], indicating a critical role of AR-V7 in CRPC progression. This evidence concerns the gene AR and Familial prostate cancer.